Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
oxybutynin
oxybutynin
- Formulary Anti-cholinergic (Overactive Bladder) Formulary
- Non-formulary
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Oxytrol for Women | FILM, EXTENDED RELEASE, TRANSDERMAL | 3.9 mg/24 hr | ||||
| Gelnique | GEL, TRANSDERMAL | 10% | ||||
| Ditropan | SYRUP, ORAL | 5 mg/5 mL | ||||
| Ditropan XL | TABLET, EXTENDED RELEASE, ORAL | 5 mg/24 hours, 10 mg/24 hours, 15 mg/24 hours | ||||
| Ditropan, Urotrol | TABLET, ORAL | 5 mg |
Last updated: Oct. 14, 2025
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
NOTES
oxybutynin (Oxytrol)
oxybutynin (Gelnique)
oxybutynin (Oxytrol for Women)
Oxytrol for Women patch is replaced twice weekly on the same two days each week
Oxytrol for Women (OTC) patch can be used on males as well as females at a much lower cost. These two patches (prescription & OTC) are essentially the same product. The OTC patch is labeled "for Women" to discourage men from self-treating overactive bladder symptoms that may warrant additional screening for BPH. There is no wording on the patch saying for women’s use only.
Reviewed: April 27, 2005, and July 28, 2009 (Gelnique), and October 28, 2014 (Oxytrol for Women)
Updated: September 2025 (Oxytrol for Women, Gelnique)
Oxybutynin Topical Products Formulary Update SBAR.pdf